Table 2.
Analysis of factors affecting vulnerability and statistical significance for their differences (p) in univariate analysis
| Variables | SARS-CoV-2 antibody positive (n = 55) | SARS-CoV-2 antibody negative (n = 445) | p |
|---|---|---|---|
| Rational use of PPE as per WHO recommendations | 85.4% | 71.5% | 0.04* |
| No. of hours of exposurea | |||
| >8 | 24.4% | 19.5% | 0.002** |
| 4–8 | 44.4% | 22.3% | |
| <4 | 31.1% | 58.2% | |
| Exposure to aerosol-generating procedures | 22.7% | 18.8% | 0.55 |
| HCQ prophylaxisb | |||
| HCQ < 6 weeks | 25% | 11.8% | 0.01* |
| 6–10 weeks | 11.4% | 22.8% | |
| >10 weeks | 2.3% | 10.7% | |
| No HCQ | 61.4% | 54.5% | |
| Presence of co-morbidity | 12 | 97 | >0.99 |
a
Only those providing direct care were included in analysis (n = 45 for the sero-positive group and n = 349 for the sero-negative group).
b
Data regarding the number of weeks of intake of HCQ was missing for 101 HCWs, hence excluded from the analysis.
Boldface p-value indicates statistical significance (*p < 0.05, **p < 0.01).